Pharmaceutical Care for A Pediatric Patient with Crohn's Disease Using Biological Agents

VernacularTitle:1例克罗恩病患儿使用生物制剂的药学监护
Author: Yao ZHANG ¹ ; Biao ZOU ; Ruxue XU ; Maimaitijiang TUERSUN ; Wenting ZHANG
Author Information

1. 华中科技大学同济医学院附属同济医院药学部,武汉 430030;深圳市龙华区人民医院药学部,深圳 518110
Keywords: Adalimumab; Crohn's disease; Biologic agent; Pharmaceutical care
From: Herald of Medicine 2024;43(12):2042-2047
CountryChina
Language:Chinese
Abstract: Objective To analyze the diagnosis and treatment process of a pediatric patient with Crohn's disease(CD)who was treated with multiple biological agents,and to provide a reference for the treatment and pharmaceutical care.Methods The diagnosis and treatment process of the pediatric patient's disease was analyzed.Drug treatment plans were evaluated through literature research to identify the entry points for pharmaceutical care and medication guidance.Results Clinical pharmacist monitored the pediatric patient's adalimumab maintenance dose,efficacy,and adverse reactions through therapeutic drug monitoring.They recommended clinical adjustments to the maintenance dose of biological agents,so that the pediatric patients could benefit from multiple aspects such as efficacy,safety,and economy.Conclusion Clinical pharmacists should follow up with pediatric patients with CD,and pay attention to medication compliance and adverse reactions in those using biological agents.